Last reviewed · How we verify
Procylin (BERAPROST)
Procylin works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow.
Procylin, also known as Beraprost, is a small molecule drug that targets the prostacyclin receptor. It is used to treat pulmonary arterial hypertension, a condition characterized by high blood pressure in the arteries of the lungs. The commercial status of Procylin is unclear, but it is likely patented. Key safety considerations include the potential for adverse effects such as headache and flushing. Procylin works by mimicking the action of prostacyclin, a natural substance that helps to relax blood vessels and improve blood flow.
At a glance
| Generic name | BERAPROST |
|---|---|
| Drug class | beraprost |
| Target | Prostacyclin receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | discontinued |
Mechanism of action
Think of it like a key that unlocks a door. Prostacyclin is a natural key that helps to relax blood vessels and improve blood flow. Procylin is a man-made key that works in a similar way, helping to open up the blood vessels and make it easier for blood to flow through them.
Approved indications
- Pulmonary arterial hypertension
Common side effects
- Right ventricular failure
- Concomitant disease aggravated
- Cardiac failure
- Pulmonary hypertension
- Brain natriuretic peptide increased
- Pulmonary arterial hypertension
- Hepatic function abnormal
- Upper respiratory tract inflammation
- Transfusion
- Anaemia
- Platelet count decreased
- Gamma-glutamyltransferase increased
Key clinical trials
- Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI (EARLY_PHASE1)
- Compassionate Use of Beraprost Sodium 314d Modified Release for Patients With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- Dose-response Study of the Safety and Efficacy of Beraprost Sodium Modified Release (BPS-MR) in Patients With Pulmonary Arterial Hypertension (PAH) (PHASE2)
- A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension (PHASE3)
- Beraprost-314d Added-on to Tyvaso® (BEAT) (PHASE3)
- A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients (PHASE2)
- An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients (PHASE2)
- Extension of BPS-MR-PAH-203 in Pulmonary Arterial Hypertension (PAH) Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Procylin CI brief — competitive landscape report
- Procylin updates RSS · CI watch RSS